aPLA2R is the first blood test specifically for nephrotic syndrome. It has recently been licensed by the FDA and we want to have an open and frank discussion on how this test may be used in clinical medicine. To aid in this discussion we will be looking at two papers.
The first was highlighted by CJASN's eJC and was covered summarized by Joel Topf and his Fellow, Bilal Saleem:
- Article Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy
- eJC forum
- Background and Summary by Topf and Saleem
- Make sure you take a look at the Editorial by Glassock (available for free if you register with eJC)
- PDF slide show summary of the article and editorial
The second article was published this past Spring in NDT. It is an industry sponsored trial of ACTH for the treatment of membranous nephropathy. Swapnil Hiremath summarized it for #NephJC
And additionally here is a link to the KDIGO Glomerulonephritis Recommendations.
Please join us on Twitter at 9pm Eastern Daylight. Use the hashtag #NephJC.